Ocular and orbital side-effects of checkpoint inhibitors: A review article

Current Opinion in Oncology

Volumn 28, Issue 4, 2016, Pages 288-294

  Antoun, Joëlle ^a,b   Titah, Cherif ^b   Cochereau, Isabelle ^b,c  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

checkpoint inhibitors; ocular side effects; orbital side effects

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT INHIBITOR; CORTICOSTEROID; STEROID; UNCLASSIFIED DRUG; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADVERSE DRUG REACTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; EYE DISEASE; EYE INFLAMMATION; GIANT CELL ARTERITIS; HUMAN; IDIOPATHIC DISEASE; IMMUNE RELATED ADVERSE EVENT; IMMUNOPATHOLOGY; KERATITIS; MELANOMA; ONCOLOGIST; OPHTHALMOLOGIST; ORBIT DISEASE; ORBIT INFLAMMATION; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; RETINOPATHY; REVIEW; RHEUMATIC POLYMYALGIA; SIDE EFFECT; STEROID THERAPY; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; UVEITIS; VOGT KOYANAGI SYNDROME; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; IMMUNOLOGY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; EYE DISEASES; HUMANS; NEOPLASMS; ORBITAL DISEASES; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84964703568     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000296     Document Type: Review

References (35)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-264.
2. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11:805-812.
3. Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 2011; 32:308-316.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
5. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373:123-135.
6. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of nonsmallcell lung cancer. N Engl J Med 2015; 372:2018-2028.
7. Kourie HR, Awada AH. Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers? Future Oncol 2015; 11:3053-3055.
8. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-144.
9. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-384.
10. Rizvi NA, Maziè res J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmall-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16:257-265.
11. Della Vittoria Scarpati G, Fusciello C, Perri F, et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. OncoTargets Ther 2014; 7:203-209.
12. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica 2013; 2013:857519.
13. Papavasileiou E, Prasad S, Freitag SK, et al. Ipilimumab-induced ocular and orbital inflammation: a case series and review of the literature. Ocul Immunol Inflamm 2016; 24:140-146.
14. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26:5950-5956.
15. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-6053.
16. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23:741-750.
17. Voskens C, Cavallaro A, Erdmann M, et al. Anticytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 2012; 30:e356-e357.
18. Robinson MR, Chan C-C, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 1997 2004; 27:478-479.
19. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncol 2014; 16:589-593.
20. Nallapaneni NN, Mourya R, Bhatt VR, et al. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Cancer Netw 2014; 12:1077-1081.
21. De Velasco G, Bermas B, Choueiri TK. Auto-immune arthropathy and uveitis as complications from PD-1 inhibitor. Arthritis Rheumatol 2016; 68:556-557.
22. Abu Samra K, Valdes-Navarro M, Lee S, et al. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol 2016; 26:e46-e48.
23. Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome. Retin Cases Brief Rep 2012; 6:423-426.
24. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-2017.
25. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:1270-1271.
26. Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol 2015; 133:965-967.
27. Crews J, Agarwal A, Jack L, et al. Ipilimumab-associated retinopathy. Ophthalmic Surg Lasers Imaging Retina 2015; 46:658-660.
28. McElnea E, N? Mhé aló id A, Moran S, et al. Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab. Orbit 2014; 33:424-427.
29. Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2011; 27:e87-e88.
30. Lecouflet M, Verschoore M, Giard C, et al. Orbital myositis associated with ipilimumab. Ann Dermatol Véné ré ologie 2013; 140 (6-7):448-451.
31. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PloS One 2013; 8:e53745.
32. Modjtahedi BS, Maibach H, Park S. Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol 2013; 32:341-343.
33. Patel M, Chan C-C. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol 2008; 30:97-110.
34. Audemard A, de Raucourt S, Miocque S, et al. Melanoma-associated retinopathy treated with ipilimumab therapy. Dermatology 2013; 227:146-149.
35. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol 2014; 66:768-769.